BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1363513)

  • 1. Immunoenzymatic assay of erbB2 protein in cancer and non-malignant breast tissue. Relationships with clinical and biochemical parameters.
    Dittadi R; Donisi PM; Brazzale A; Marconato R; Spina M; Gion M
    Anticancer Res; 1992; 12(6B):2005-10. PubMed ID: 1363513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method.
    Dittadi R; Brazzale A; Pappagallo G; Salbe C; Nascimben O; Rosabian A; Gion M
    Anticancer Res; 1997; 17(2B):1245-7. PubMed ID: 9137481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progesterone-binding cyst protein (PBCP = GCDFP-24) and steroid hormone receptors as markers of differentiation in breast cancer. Inverse relation of distribution in normal and malignant tissue of the same breast.
    Søreide JA; Lea OA; Kvinnsland S
    Anticancer Res; 1991; 11(3):1323-6. PubMed ID: 1888167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Yang JQ; Chen L; Xing TY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERBB2 amplification in breast cancer with a high rate of proliferation.
    Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
    Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum c-erbB-2 protein in breast cancer patients.
    Chearskul S; Sinlarat P; Bhothisuwan K; Churintrapun M; Ornrhebroi S; Klinsala N; Sungkabunchoo S
    J Med Assoc Thai; 2000 Aug; 83(8):886-93. PubMed ID: 10998842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of steroid receptors with histopathologic characteristics in breast carcinoma.
    Bhatavdekar JM; Trivedi SN; Shah NG; Karelia NH; Patel DD; Giri DD; Patel TB
    Neoplasma; 1988; 35(4):413-23. PubMed ID: 3185838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
    Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
    BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-pathological correlations.
    Cuny M; Simony-Lafontaine J; Rouanet P; Grenier J; Valles H; Lavaill R; Louason G; Causse A; Lequeux N; Thierry C
    Oncol Res; 1994; 6(4-5):169-76. PubMed ID: 7841539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
    Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
    J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay.
    Narita T; Funahashi H; Satoh Y; Imai T; Takagi H
    Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between western blotting, immunohistochemical and ELISA assay for p185neu quantitation in breast cancer specimens.
    Dittadi R; Catozzi L; Gion M; Brazzale A; Capitanio G; Gelli MC; Menegon A; Gardini G; Malagutti R; Piffanelli A
    Anticancer Res; 1993; 13(5C):1821-4. PubMed ID: 7903522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Ivanov O; Chen F; Wiley EL; Keswani A; Diaz LK; Memmel HC; Rademaker A; Gradishar WJ; Morrow M; Khan SA; Cryns VL
    Breast Cancer Res Treat; 2008 Oct; 111(3):411-7. PubMed ID: 17968656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
    Wilbur DC; Barrows GH
    Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
    Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
    Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
    Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
    Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.